干细胞治疗逆转肝硬化的临床试验

StephenW

Clinical trial for stem-cell therapy to reverse liver cirrhosis
Published
Jul 11, 2017, 1:24 pm SGT
Facebook54
Twitter
Email
Yap Li Yin

SINGAPORE - the use of stem cells to reverse liver cirrhosis - or the hardening of the liver - is being explored in a clinical trial.

Conducted by a multi-center team led by the National University Hospital (NUH), seek aim to determine if stem cell therapy can improve liver function.

Previously, liver cirrhosis, caused by various diseases such as chronic hepatitis B and non-alcoholic fatty liver disease, was thought to be irreversible.

A liver transfer provides a definitive cure to end-stage cirrhosis.
Get The Straits Times
Newsletters in your inbox
Sign Up

However, in Singapore, less than 5 per cent of end-stage liver cirrhosis patients receive a liver transplant.

The number of people on the waiting list for a liver transplant has been increased over the years, according to statistics from the Ministry of Health.

In 2007, there were nine on the waiting list, compared with 57 last year. There are around 50 waiting for a liver transplant this year.

Also, many patients do not fulfil the eligibility criteria to receive a liver transplant due to other health complications or being above the age limit of 70 years.

The $ 26 million study, which was launched on Tuesday (July 11), is funded by the National Medical Research Council and 46 patients will be recruited for it. It will run for four years and patients will not need to bear the costs of the stem Cell treatment.

Stem cells will be taken from a patient's own bone marrow and will be isolated and injected into into the patient's liver to initiate the repair.

Similar therapy treatments have been conducted overseas in countries such as Egypt and India, although they have not been fully evaluated for efficacy.

Associate Professor Dan Yock Young, a senior consultant in the division of gastroenterology and hepatology at NUH, said: "We are conducting the study in a systematic and scientific manner to get definitive evidence of the effects of the treatment."

He also notes that the stem cell therapy is not a substitute for a liver transplant. "This treatment is not intended to pull patients off the waiting list, but provide an option for those who are not eligible for a transplant.

StephenW

干细胞治疗逆转肝硬化的临床试验
发布时间
2017年7月11日，下午1:24
Facebook54
推特
电子邮件
叶Li

新加坡 - 临床试验正在探索干细胞逆转肝硬化或肝硬化的用途。

由国立大学医院（NUH）领导的多中心小组进行，旨在确定干细胞治疗是否可以改善肝功能。

以前，由慢性乙型肝炎和非酒精性脂肪性肝病等各种疾病引起的肝硬化被认为​​是不可逆转的。

肝转移提供终末期肝硬化的明确治疗方法。
获得海峡时报
收件箱中的通讯
注册

然而，在新加坡，不到5％的终末期肝硬化患者接受了肝移植。

据卫生部统计，多年来，肝移植等候名单数量有所增加。

2007年，等候名单上有9个，去年为57个。今年有大约50人等待肝移植。

此外，许多患者由于其他健康并发症或年龄超过70岁而不符合接受肝移植的资格标准。

这项价值2600万美元的研究于星期二（7月11日）发布，由国家医学研究理事会资助，其中46名患者将被招募。它将运行四年，患者不需要承担干细胞治疗的费用。

干细胞将从患者自己的骨髓中取出，并被分离并注入患者的肝脏以开始修复。

虽然对埃及和印度等国家进行了类似的治疗，但尚未得到充分的评估。

NUH胃肠病学和肝脏病学高级顾问副教授Dan Yock Young说：“我们以系统和科学的方式进行研究，以获得治疗效果的明确证据。”

他还指出，干细胞治疗不能代替肝移植。 “这种治疗方法并不是为了将病人从等候名单上拉下来，而是为那些不符合移植资格的人提供一个选择。